Evaluation of the Possible Benefits of Breast Cancer Screening in Women Aged 40 to 49 Years in the Steel Valley Region, Brazil

Cátia Cilene AIRES LIMA (1), Carla Daruich de Souza (2)
(1) Nuclear and Energy Research Institute, Márcio Cunha Hospital, Ipatinga, Minas Gerias, Brazil, Brazil,
(2) Nuclear and Energy Research Institute, Márcio Cunha Hospital, Ipatinga, Minas Gerias, Brazil, Brazil

Abstract

Introduction: This study investigates the effectiveness of mammographic screening for women aged 40 to 49 in Brazil's Steel Valley Region. Despite a Ministry of Health recommendation to start screenings at 50, 25% of breast cancer cases occur in the 40-49 age group. Methods: The retrospective analysis, spanning 2008-2019 at Marcio Cunha Hospital, compared two groups: cancer diagnosed via screening mammography (277) and diagnostic mammography (229). Results: Results showed delayed diagnoses for non-screened women, with a fivefold higher mortality rate. Screening facilitated earlier detection of less malignant cancers (85.9% vs. 43.7%). Women diagnosed through screening were more likely to preserve their breasts (28.9% vs. 55.5% for Radical Breast Surgery and 71.1% vs. 28.9% for Breast-Sparing Surgery), and fewer axillary lymphadenectomies were performed. Discussion: Recommendations include enhancing public awareness and establishing a breast cancer surveillance service. Conclusion: The findings support extending screening mammography access to all women over 40 in the Steel Valley region and underscore the need for broader-scale research in other areas.

Full text article

Generated from XML file

References

Federação Brasileira das Associações de Ginecologia e Obstetrícia. Manual de Orientação Mastologia. https://www.febrasgo.org.br/pt/component/zoo/category/mastologia; 2010.

American College of Physicians. ACP issues guidance statement for breast cancer screening of average-risk women with no symptoms https://www.acponline.org/acp-newsroom/acp-issues-guidance-statement-for-breast-cancer-screening-of-average-risk-women-with-no-symptoms2022 [

World Heath Organization. Breast cancer now most common form of cancer: WHO taking action https://www.who.int/news/item/03-02-2021-breast-cancer-now-most-common-form-of-cancer-who-taking-action2021 [

MINISTÉRIO DA SAÚDE - INSTITUTO NACIONAL DO CÂNCER. Controle do câncer de mama/ conceito e magnitude. https://www.inca.gov.br/controle-do-cancer-de-mama/conceito-e-magnitude2022 [

Rosa DD, Bines J, Werutsky G, Barrios CH, Cronemberger E, Queiroz GS, et al. The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). Breast Cancer Res Treat. 2020;183(3):749-57.

Hospital Márcio Cunha. Sobre nós https://www.anahp.com.br/associado/hospital-marcio-cunha/2022 [

Estado de Minas Gerais - Região Metropolitana do Vale do Aço. Conheça os municípios https://www.agenciarmva.mg.gov.br/conheca-os-municipios/2022 [

National Cancer Institute. AJCC staging system https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ajcc-staging-system2022 [

Thomssen C, Balic M, Harbeck N, Gnant M. St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. Breast Care (Basel). 2021;16(2):135-43.

Webb ML, Cady B, Michaelson JS, Bush DM, Calvillo KZ, Kopans DB, et al. A failure analysis of invasive breast cancer: most deaths from disease occur in women not regularly screened. Cancer. 2014;120(18):2839-46.

Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012;12(1):96-110.

Ghiasvand R, Adami HO, Harirchi I, Akrami R, Zendehdel K. Higher incidence of premenopausal breast cancer in less developed countries; myth or truth? BMC Cancer. 2014;14:343.

Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, et al. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16(5):446.

Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, et al. Health and Racial Disparity in Breast Cancer. Adv Exp Med Biol. 2019;1152:31-49.

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5).

Corrêa PB, Toralles MBP, Abe-Sandes K, Machado TMB, Bonfim TF, Meyer L, et al. Câncer de mama triplo negativo e sua associação com ancestralidade africana. Revista de Ciências Médicas e Biológicas. 2010;9(1):3-7.

Simon SD, Bines J, Werutsky G, Nunes JS, Pacheco FC, Segalla JG, et al. Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast. 2019;44:113-9.

Tonelli M, Connor Gorber S, Joffres M, Dickinson J, Singh H, Lewin G, et al. Recommendations on screening for breast cancer in average-risk women aged 40-74 years. Cmaj. 2011;183(17):1991-2001.

Tabár L, Dean PB, Chen TH, Yen AM, Chen SL, Fann JC, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2019;125(4):515-23.

Alanko J, Tanner M, Vanninen R, Auvinen A, Isola J. Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast Cancer Res Treat. 2021;187(1):267-74.

Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol. 2015;16(9):1123-32.

Destounis S, Santacroce A. Age to Begin and Intervals for Breast Cancer Screening: Balancing Benefits and Harms. AJR Am J Roentgenol. 2018;210(2):279-84.

Monticciolo DL, Newell MS, Hendrick RE, Helvie MA, Moy L, Monsees B, et al. Breast Cancer Screening for Average-Risk Women: Recommendations From the ACR Commission on Breast Imaging. J Am Coll Radiol. 2017;14(9):1137-43.

Ray KM, Joe BN, Freimanis RI, Sickles EA, Hendrick RE. Screening Mammography in Women 40-49 Years Old: Current Evidence. AJR Am J Roentgenol. 2018;210(2):264-70.

Ernst MF, Voogd AC, Coebergh JW, Repelaer van Driel OJ, Roukema JA. The introduction of mammographical screening has had little effect on the trend in breast-conserving surgery: a population-based study in Southeast Netherlands. Eur J Cancer. 2001;37(18):2435-40.

Paci E, Duffy SW, Giorgi D, Zappa M, Crocetti E, Vezzosi V, et al. Are breast cancer screening programmes increasing rates of mastectomy? Observational study. BMJ. 2002;325(7361):418.

Lefeuvre D, Catajar N, Le Bihan Benjamin C, Ifrah N, De Bels F, Viguier J, et al. Breast cancer screening: Impact on care pathways. Cancer Med. 2019;8(8):4070-8.

Samnakay N, Tinning J, Ives A, Willsher P, Archer S, Wylie E, et al. Rates for mastectomy are lower in women attending a breast-screening programme. ANZ J Surg. 2005;75(11):936-9.

Hidding JT, Beurskens CH, van der Wees PJ, van Laarhoven HW, Nijhuis-van der Sanden MW. Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review. PLoS One. 2014;9(5):e96748.

INSTITUTO NACIONAL DE CÂNCER. Monitoramento das ações de controle dos cânceres de mama. https://www.inca.gov.br/publicacoes/informativos/informativo-deteccao-precoce-no-2-2021; 2021. Contract No.: Boletim ano 12, no 2.

Brazil Deputy Chamber. Law Nº 13.896 https://www2.camara.leg.br/legin/fed/lei/2019/lei-13896-30-outubro-2019-789326-publicacaooriginal-159304-pl.html2012 [

Abstract graphic free copyright image

Available at: https://br.freepik.com/fotos-vetores-gratis/design-plano

Created by freepik - br.freepik.com

Authors

Cátia Cilene AIRES LIMA
Carla Daruich de Souza
carladdsouza@yahoo.com.br (Primary Contact)
1.
AIRES LIMA CC, Daruich de Souza C. Evaluation of the Possible Benefits of Breast Cancer Screening in Women Aged 40 to 49 Years in the Steel Valley Region, Brazil. Arch Breast Cancer [Internet]. [cited 2024 Feb. 22];11(2). Available from: https://archbreastcancer.com/index.php/abc/article/view/842

Article Details